Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)-Reference-Cited by-同舟云学术

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Published:2013-01-08 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Naeim Arash,Henk Henry J,Becker Laura,Chia Victoria,Badre Sejal,Li Xiaoyan,Deeter Robert

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-11.pdf

Reference29 articles.

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005, 103 (9): 1916-1924. 10.1002/cncr.20983.

2. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004, 100 (2): 228-237. 10.1002/cncr.11882.

3. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006, 106 (10): 2258-2266. 10.1002/cncr.21847.

4. Lyman GH, Kuderer N, Greene J, Balducci L: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998, 34 (12): 1857-1864. 10.1016/S0959-8049(98)00222-6.

5. Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002, 62 (Suppl 1): 65-78.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study;Journal of Modern Oncology;2024-07-03

2. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051;Scientific Reports;2024-02-15

3. Effectiveness and Safety of Originator and Biosimilar G-CSF as Primary Prophylaxis in DLBCL: A Cohort Study and Meta-Analysis;2023-09-11

4. Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study;PLOS ONE;2023-07-17

5. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study;Cancer Control;2023-01-04